This page has only limited features, please log in for full access.

Unclaimed
M. C. Verhaar
Department of Nephrology & Hypertension, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 04 August 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

Objective: The 2020 Global Vascular Guidelines aim at improving decision making in Chronic Limb-Threatening Ischemia (CLTI) by providing a framework for evidence-based revascularization. Herein, the Global Limb Anatomic Staging System (GLASS) serves to estimate the chance of success and patency of arterial pathway revascularization based on the extent and distribution of the atherosclerotic lesions. We report the preliminary feasibility results and observer variability of the GLASS. GLASS is a part of the new global guideline and posed as a promising additional tool for EBR strategies to predict the success of lower extremity arterial revascularization. This study reports on the consistency of GLASS scoring to maximize inter-observer agreement and facilitate its application. Methods: GLASS separately scores the femoropopliteal (FP) and infrapopliteal (IP) segment based on stenosis severity, lesion length and the extent of calcification within the target artery pathway (TAP). In our stepwise approach, we used two angiographic datasets. Each following step was based on the lessons learned from the previous step. The primary outcome was inter-observer agreement measured as Cohen’s Kappa, scored by two (step 1 + 2) and four (step 3) blinded and experienced observers, respectively. Steps 1 (n = 139) and 2 (n = 50) were executed within a dataset of a Dutch interventional RCT in CLTI. Step 3 (n = 100) was performed in randomly selected all-comer CLTI patients from two vascular centers in the United States. Results: In step 1, kappa values were 0.346 (FP) and 0.180 (IP). In step 2, applied in the same dataset, the use of other experienced observers and a provided TAP, resulted in similar low kappa values 0.406 (FP) and 0.089 (IP). Subsequently, in step 3, the formation of an altered stepwise approach using component scoring, such as separate scoring of calcification and adding a ruler to the images resulted in kappa values increasing to 0.796 (FP) and 0.730 (IP). Conclusion: This retrospective GLASS validation study revealed low inter-observer agreement for unconditioned scoring. A stepwise component scoring provides acceptable agreement and a solid base for further prospective validation studies to investigate how GLASS relates to treatment outcomes.

ACS Style

Joep Wijnand; Devin Zarkowsky; Bian Wu; Steven van Haelst; Evert-Jan Vonken; Thomas Sorrentino; Zachary Pallister; Jayer Chung; Joseph Mills; Martin Teraa; Marianne Verhaar; Gert de Borst; Michael Conte. The Global Limb Anatomic Staging System (GLASS) for CLTI: Improving Inter-Observer Agreement. Journal of Clinical Medicine 2021, 10, 3454 .

AMA Style

Joep Wijnand, Devin Zarkowsky, Bian Wu, Steven van Haelst, Evert-Jan Vonken, Thomas Sorrentino, Zachary Pallister, Jayer Chung, Joseph Mills, Martin Teraa, Marianne Verhaar, Gert de Borst, Michael Conte. The Global Limb Anatomic Staging System (GLASS) for CLTI: Improving Inter-Observer Agreement. Journal of Clinical Medicine. 2021; 10 (16):3454.

Chicago/Turabian Style

Joep Wijnand; Devin Zarkowsky; Bian Wu; Steven van Haelst; Evert-Jan Vonken; Thomas Sorrentino; Zachary Pallister; Jayer Chung; Joseph Mills; Martin Teraa; Marianne Verhaar; Gert de Borst; Michael Conte. 2021. "The Global Limb Anatomic Staging System (GLASS) for CLTI: Improving Inter-Observer Agreement." Journal of Clinical Medicine 10, no. 16: 3454.

Journal article
Published: 23 May 2021 in Biology
Reads 0
Downloads 0

The preclinical evaluation of novel therapies for chronic kidney disease requires a simple method for the assessment of kidney function in a uremic large animal model. An intravenous bolus of iohexol was administered to goats (13 measurements in n = 3 goats) and pigs (23 measurements in n = 5 pigs) before and after induction of kidney failure, followed by frequent blood sampling up to 1440 min. Plasma clearance (CL) was estimated by a nonlinear mixed-effects model (CLNLME) and by a one-compartmental pharmacokinetic disposition model using iohexol plasma concentrations during the terminal elimination phase (CL1CMT). A simple method (CLSM) for the calculation of plasma clearance was developed based on the most appropriate relationship between CLNLME and CL1CMT. CLSM and CLNLME showed good agreement (CLNLME/CLSM ratio: 1.00 ± 0.07; bias: 0.03 ± 1.64 mL/min; precision CLSM and CLNLME: 80.9% and 80.7%, respectively; the percentage of CLSM estimates falling within ±30% (P30) or ±10% (P10) of CLNLME: 53% and 12%, respectively). For mGFRNLME vs. mGFRSM, bias was −0.25 ± 2.24 and precision was 49.2% and 53.6%, respectively, P30 and P10 for mGFR based on CLSM were 71% and 24%, respectively. A simple method for measurement of GFR in healthy and uremic goats and pigs was successfully developed, which eliminates the need for continuous infusion of an exogenous marker, urine collection and frequent blood sampling.

ACS Style

Maaike van Gelder; Jasper Stevens; Tobias Pieters; Koen Vaessen; Jaap Joles; Marianne Verhaar; Karin Gerritsen. Simplified Iohexol-Based Method for Measurement of Glomerular Filtration Rate in Goats and Pigs. Biology 2021, 10, 461 .

AMA Style

Maaike van Gelder, Jasper Stevens, Tobias Pieters, Koen Vaessen, Jaap Joles, Marianne Verhaar, Karin Gerritsen. Simplified Iohexol-Based Method for Measurement of Glomerular Filtration Rate in Goats and Pigs. Biology. 2021; 10 (6):461.

Chicago/Turabian Style

Maaike van Gelder; Jasper Stevens; Tobias Pieters; Koen Vaessen; Jaap Joles; Marianne Verhaar; Karin Gerritsen. 2021. "Simplified Iohexol-Based Method for Measurement of Glomerular Filtration Rate in Goats and Pigs." Biology 10, no. 6: 461.

Journal article
Published: 03 April 2021 in Biology
Reads 0
Downloads 0

A large animal model of (end-stage) kidney disease (ESKD) is needed for the preclinical testing of novel renal replacement therapies. This study aimed to create stable uremia via subtotal renal artery embolization in goats and induce a temporary further decline in kidney function by administration of gentamicin. Renal artery embolization was performed in five Dutch white goats by infusing polyvinyl alcohol particles in branches of the renal artery, aiming for the embolization of ~80% of one kidney and complete embolization of the contralateral kidney. Gentamicin was administered to temporarily further increase the plasma concentrations of uremic toxins. After initial acute kidney injury, urea and creatinine plasma concentrations stabilized 1.5 ± 0.7 months post-embolization and remained elevated (12 ± 1.4 vs. 5.6 ± 0.8 mmol/L and 174 ± 45 vs. 65 ± 5.6 µmol/L, resp.) during follow-up (16 ± 6 months). Gentamicin induced temporary acute-on-chronic kidney injury with a variable increase in plasma concentrations of small solutes (urea 29 ± 15 mmol/L, creatinine 841 ± 584 µmol/L, phosphate 2.2 ± 0.3 mmol/L and potassium 5.0 ± 0.6 mmol/L) and protein-bound uremic toxins representative of patients with ESKD. A uremic goat model characterized by stable moderate uremia was established via subtotal renal artery embolization with the induction of temporary severe acute-on-chronic kidney injury by the administration of gentamicin, allowing preclinical in vivo validation of novel renal replacement technologies.

ACS Style

Maaike van Gelder; Joost de Vries; Sabbir Ahmed; Anneke Monninkhof; Gérard de Kort; Evert-Jan Vonken; Diënty Hazenbrink; Koen Vaessen; Tri Nguyen; Marianne Verhaar; Jaap Joles; Karin Gerritsen. A Uremic Goat Model Created by Subtotal Renal Artery Embolization and Gentamicin. Biology 2021, 10, 292 .

AMA Style

Maaike van Gelder, Joost de Vries, Sabbir Ahmed, Anneke Monninkhof, Gérard de Kort, Evert-Jan Vonken, Diënty Hazenbrink, Koen Vaessen, Tri Nguyen, Marianne Verhaar, Jaap Joles, Karin Gerritsen. A Uremic Goat Model Created by Subtotal Renal Artery Embolization and Gentamicin. Biology. 2021; 10 (4):292.

Chicago/Turabian Style

Maaike van Gelder; Joost de Vries; Sabbir Ahmed; Anneke Monninkhof; Gérard de Kort; Evert-Jan Vonken; Diënty Hazenbrink; Koen Vaessen; Tri Nguyen; Marianne Verhaar; Jaap Joles; Karin Gerritsen. 2021. "A Uremic Goat Model Created by Subtotal Renal Artery Embolization and Gentamicin." Biology 10, no. 4: 292.

Original article
Published: 29 March 2021 in Journal of Polymer Science
Reads 0
Downloads 0

Supramolecular biomaterials based on ureido‐pyrimidinone (UPy) moieties are versatile polymer materials as their function can be tailored to the application. These UPy‐materials can be designed into polymer coatings, self‐healing polymers, hydrogels and elastomers. The biocompatibility of UPy‐based materials and their degradation products is a long‐term success requirement for many regenerative medicine and biomedical applications. Earlier research has shown that UPy‐based materials and polymers display no immediate toxic effects, but in‐depth in‐vitro studies on potential UPy‐polymer degradation products have not been executed. Owing to their resemblance to naturally occurring purines and pyrimidines, UPy‐compounds and their degradation products could potentially initiate an immune response or be mutagenic. Accordingly, 11 selected UPy‐compounds were synthesized, and their effect on cell viability, wound healing, and their immunogenicity and potential mutagenic potential, were studied. We showed that low molecular weight degradation products of UPy‐based biomaterials do not affect cell viability, nor do these interfere with several aspects of endothelial function including proliferation, angiogenic sprouting and cellular migration even in levels exceeding plausibly attainable concentrations. Furthermore, the compounds are neither immunogenic nor mutagenic, showing that UPy‐biomaterials exhibit good biocompatibility in vitro, and could in principle be used in humans.

ACS Style

Paul J. Besseling; Tristan Mes; Anton W. Bosman; Joris W. Peeters; Henk M. Janssen; Maarten H. Bakker; Joost O. Fledderus; Martin Teraa; Marianne C. Verhaar; Hendrik Gremmels; Patricia Y. W. Dankers. The in‐vitro biocompatibility of ureido‐pyrimidinone compounds and polymer degradation products. Journal of Polymer Science 2021, 59, 1267 -1277.

AMA Style

Paul J. Besseling, Tristan Mes, Anton W. Bosman, Joris W. Peeters, Henk M. Janssen, Maarten H. Bakker, Joost O. Fledderus, Martin Teraa, Marianne C. Verhaar, Hendrik Gremmels, Patricia Y. W. Dankers. The in‐vitro biocompatibility of ureido‐pyrimidinone compounds and polymer degradation products. Journal of Polymer Science. 2021; 59 (12):1267-1277.

Chicago/Turabian Style

Paul J. Besseling; Tristan Mes; Anton W. Bosman; Joris W. Peeters; Henk M. Janssen; Maarten H. Bakker; Joost O. Fledderus; Martin Teraa; Marianne C. Verhaar; Hendrik Gremmels; Patricia Y. W. Dankers. 2021. "The in‐vitro biocompatibility of ureido‐pyrimidinone compounds and polymer degradation products." Journal of Polymer Science 59, no. 12: 1267-1277.

Protocol
Published: 05 March 2021 in Nature Protocols
Reads 0
Downloads 0

Advanced in vitro kidney models are of great importance to the study of renal physiology and disease. Kidney tubuloids can be established from primary cells derived from adult kidney tissue or urine. Tubuloids are three-dimensional multicellular structures that recapitulate tubular function and have been used to study infectious, malignant, metabolic, and genetic diseases. For tubuloids to more closely represent the in vivo kidney, they can be integrated into an organ-on-a-chip system that has a more physiological tubular architecture and allows flow and interaction with vasculature or epithelial and mesenchymal cells from other organs. Here, we describe a detailed protocol for establishing tubuloid cultures from tissue and urine (1–3 weeks), as well as for generating and characterizing tubuloid cell–derived three-dimensional tubular structures in a perfused microfluidic multi-chip platform (7 d). The combination of the two systems yields a powerful in vitro tool that better recapitulates the complexity of the kidney tubule with donor-specific properties. Clevers et al. describe the establishment of tubuloid cultures from tissue and urine, as well as the generation and characterization of tubuloid cell–derived 3D tubular structures in a perfused microfluidic multi-chip platform.

ACS Style

Linda Gijzen; Fjodor A. Yousef Yengej; Frans Schutgens; Marianne K. Vormann; Carola M. E. Ammerlaan; Arnaud Nicolas; Dorota Kurek; Paul Vulto; Maarten B. Rookmaaker; Henriette L. Lanz; Marianne C. Verhaar; Hans Clevers. Culture and analysis of kidney tubuloids and perfused tubuloid cells-on-a-chip. Nature Protocols 2021, 16, 2023 -2050.

AMA Style

Linda Gijzen, Fjodor A. Yousef Yengej, Frans Schutgens, Marianne K. Vormann, Carola M. E. Ammerlaan, Arnaud Nicolas, Dorota Kurek, Paul Vulto, Maarten B. Rookmaaker, Henriette L. Lanz, Marianne C. Verhaar, Hans Clevers. Culture and analysis of kidney tubuloids and perfused tubuloid cells-on-a-chip. Nature Protocols. 2021; 16 (4):2023-2050.

Chicago/Turabian Style

Linda Gijzen; Fjodor A. Yousef Yengej; Frans Schutgens; Marianne K. Vormann; Carola M. E. Ammerlaan; Arnaud Nicolas; Dorota Kurek; Paul Vulto; Maarten B. Rookmaaker; Henriette L. Lanz; Marianne C. Verhaar; Hans Clevers. 2021. "Culture and analysis of kidney tubuloids and perfused tubuloid cells-on-a-chip." Nature Protocols 16, no. 4: 2023-2050.

Journal article
Published: 01 March 2021 in Tissue Engineering Part C: Methods
Reads 0
Downloads 0

The kidneys are essential for maintaining electrolyte homeostasis. Blood electrolyte composition is controlled by active reabsorption and secretion processes in dedicated segments of the kidney tubule. Specifically, the distal convoluted tubule (DCT) and connecting tubule are important for regulating the final excretion of sodium, magnesium, and calcium. Studies unravelling the specific function of these segments have greatly improved our understanding of DCT (patho)physiology. Over the years, experimental models used to study the DCT have changed and the field has advanced from early dissection studies with rats and rabbits to the use of various transgenic mouse models. Developments in dissection techniques and cell culture methods have resulted in immortalized mouse DCT cell lines and made it possible to specifically obtain DCT fragments for ex vivo studies. However, we still do not fully understand the complex (patho)physiology of this segment and there is need for advanced human DCT models. Recently, kidney organoids and tubuloids have emerged as new complex cell models that provide excellent opportunities for physiological studies, disease modelling, drug discovery, and even personalized medicine in the future. This review presents an overview of cell models used to study the DCT and provides an outlook on kidney organoids and tubuloids as model for DCT (patho)physiology.

ACS Style

Miss Charlotte J.A. Olde Hanhof; Fjodor A. Yousef Yengej; Maarten B. Rookmaaker; Marianne C. Verhaar; Jenny van der Wijst; Joost G. Hoenderop. Modeling Distal Convoluted Tubule (Patho)Physiology: An Overview of Past Developments and an Outlook Toward the Future. Tissue Engineering Part C: Methods 2021, 27, 200 -212.

AMA Style

Miss Charlotte J.A. Olde Hanhof, Fjodor A. Yousef Yengej, Maarten B. Rookmaaker, Marianne C. Verhaar, Jenny van der Wijst, Joost G. Hoenderop. Modeling Distal Convoluted Tubule (Patho)Physiology: An Overview of Past Developments and an Outlook Toward the Future. Tissue Engineering Part C: Methods. 2021; 27 (3):200-212.

Chicago/Turabian Style

Miss Charlotte J.A. Olde Hanhof; Fjodor A. Yousef Yengej; Maarten B. Rookmaaker; Marianne C. Verhaar; Jenny van der Wijst; Joost G. Hoenderop. 2021. "Modeling Distal Convoluted Tubule (Patho)Physiology: An Overview of Past Developments and an Outlook Toward the Future." Tissue Engineering Part C: Methods 27, no. 3: 200-212.

Journal article
Published: 01 March 2021 in Tissue Engineering Part C: Methods
Reads 0
Downloads 0

Inherited kidney tubulopathies comprise a group of rare diseases with a significant societal impact, as lifelong treatment is often required and no therapies are available to prevent progression of renal damage. Diagnosis of inherited tubulopathies has improved with the advances of next generation sequencing. However, difficulties remain, such as a lack of genotype-phenotype correlation and unknown pathogenicity of newly identified variants. In addition, treatment remains mainly symptomatic. Both diagnosis and treatment can be improved by addition of in vitro functional studies to clinical care. Urine-derived kidney organoids (‘tubuloids’) are a promising platform for these studies. International collections of patient-derived tubuloids in a living biobank offer additional advantages for drug development and pathophysiological studies. In this review, we discuss how diagnosis and treatment of tubulopathies can be improved by in vitro studies using a tubuloid biobank. We also address practical challenges in the development of such biobank.

ACS Style

Frans Schutgens; Maarten B Rookmaaker; Marianne C Verhaar. A Perspective on a Urine-Derived Kidney Tubuloid Biobank from Patients with Hereditary Tubulopathies. Tissue Engineering Part C: Methods 2021, 27, 177 -182.

AMA Style

Frans Schutgens, Maarten B Rookmaaker, Marianne C Verhaar. A Perspective on a Urine-Derived Kidney Tubuloid Biobank from Patients with Hereditary Tubulopathies. Tissue Engineering Part C: Methods. 2021; 27 (3):177-182.

Chicago/Turabian Style

Frans Schutgens; Maarten B Rookmaaker; Marianne C Verhaar. 2021. "A Perspective on a Urine-Derived Kidney Tubuloid Biobank from Patients with Hereditary Tubulopathies." Tissue Engineering Part C: Methods 27, no. 3: 177-182.

Editorial
Published: 01 February 2021 in Tissue Engineering Part C: Methods
Reads 0
Downloads 0

Tissue Engineering Part C: Methods

ACS Style

Ying Chen; Marianne C. Verhaar. Editorial for Special Issue on Drug and Disease Testing Model Systems. Tissue Engineering Part C: Methods 2021, 27, 47 -48.

AMA Style

Ying Chen, Marianne C. Verhaar. Editorial for Special Issue on Drug and Disease Testing Model Systems. Tissue Engineering Part C: Methods. 2021; 27 (2):47-48.

Chicago/Turabian Style

Ying Chen; Marianne C. Verhaar. 2021. "Editorial for Special Issue on Drug and Disease Testing Model Systems." Tissue Engineering Part C: Methods 27, no. 2: 47-48.

Review
Published: 14 September 2020 in International Journal of Molecular Sciences
Reads 0
Downloads 0

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are pivotal regulators of extracellular matrix (ECM) composition and could, due to their dynamic activity, function as prognostic tools for fibrosis and cardiac function in left ventricular diastolic dysfunction (LVDD) and heart failure with preserved ejection fraction (HFpEF). We conducted a systematic review on experimental animal models of LVDD and HFpEF published in MEDLINE or Embase. Twenty-three studies were included with a total of 36 comparisons that reported established LVDD, quantification of cardiac fibrosis and cardiac MMP or TIMP expression or activity. LVDD/HFpEF models were divided based on underlying pathology: hemodynamic overload (17 comparisons), metabolic alteration (16 comparisons) or ageing (3 comparisons). Meta-analysis showed that echocardiographic parameters were not consistently altered in LVDD/HFpEF with invasive hemodynamic measurements better representing LVDD. Increased myocardial fibrotic area indicated comparable characteristics between hemodynamic and metabolic models. Regarding MMPs and TIMPs; MMP2 and MMP9 activity and protein and TIMP1 protein levels were mainly enhanced in hemodynamic models. In most cases only mRNA was assessed and there were no correlations between cardiac tissue and plasma levels. Female gender, a known risk factor for LVDD and HFpEF, was underrepresented. Novel studies should detail relevant model characteristics and focus on MMP and TIMP protein expression and activity to identify predictive circulating markers in cardiac ECM remodeling.

ACS Style

Merle M. Krebber; Christian G. M. Van Dijk; Robin W. M. Vernooij; Maarten M. Brandt; Craig A. Emter; Christoph D. Rau; Joost O. Fledderus; Dirk J. Duncker; Marianne C. Verhaar; Caroline Cheng; Jaap A. Joles. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 2020, 21, 6742 .

AMA Style

Merle M. Krebber, Christian G. M. Van Dijk, Robin W. M. Vernooij, Maarten M. Brandt, Craig A. Emter, Christoph D. Rau, Joost O. Fledderus, Dirk J. Duncker, Marianne C. Verhaar, Caroline Cheng, Jaap A. Joles. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2020; 21 (18):6742.

Chicago/Turabian Style

Merle M. Krebber; Christian G. M. Van Dijk; Robin W. M. Vernooij; Maarten M. Brandt; Craig A. Emter; Christoph D. Rau; Joost O. Fledderus; Dirk J. Duncker; Marianne C. Verhaar; Caroline Cheng; Jaap A. Joles. 2020. "Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis." International Journal of Molecular Sciences 21, no. 18: 6742.

Journal article
Published: 01 September 2020 in Tissue Engineering Part C: Methods
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part C: Methods 2020, 26, 458 -458.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part C: Methods. 2020; 26 (9):458-458.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part C: Methods 26, no. 9: 458-458.

Other
Published: 01 September 2020 in Tissue Engineering Part A
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part A 2020, 26, 928 -928.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part A. 2020; 26 (17-18):928-928.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part A 26, no. 17-18: 928-928.

Journal article
Published: 01 August 2020 in Tissue Engineering Part B: Reviews
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part B: Reviews 2020, 26, 296 -296.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part B: Reviews. 2020; 26 (4):296-296.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part B: Reviews 26, no. 4: 296-296.

Journal article
Published: 01 August 2020 in Tissue Engineering Part C: Methods
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part C: Methods 2020, 26, 398 -398.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part C: Methods. 2020; 26 (8):398-398.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part C: Methods 26, no. 8: 398-398.

Journal article
Published: 01 August 2020 in Tissue Engineering Part A
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part A 2020, 26, 830 -830.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part A. 2020; 26 (15-16):830-830.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part A 26, no. 15-16: 830-830.

Other
Published: 01 July 2020 in Tissue Engineering Part C: Methods
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part C: Methods 2020, 26, 348 -348.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part C: Methods. 2020; 26 (7):348-348.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part C: Methods 26, no. 7: 348-348.

Journal article
Published: 01 July 2020 in Tissue Engineering Part A
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part A 2020, 26, 824 -824.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part A. 2020; 26 (13-14):824-824.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part A 26, no. 13-14: 824-824.

Journal article
Published: 12 June 2020 in Toxins
Reads 0
Downloads 0

In chronic kidney disease (CKD), the secretion of uremic toxins is compromised leading to their accumulation in blood, which contributes to uremic complications, in particular cardiovascular disease. Organic anion transporters (OATs) are involved in the tubular secretion of protein-bound uremic toxins (PBUTs). However, OATs also handle a wide range of drugs, including those used for treatment of cardiovascular complications and their interaction with PBUTs is unknown. The aim of this study was to investigate the interaction between commonly prescribed drugs in CKD and endogenous PBUTs with respect to OAT1-mediated uptake. We exposed a unique conditionally immortalized proximal tubule cell line (ciPTEC) equipped with OAT1 to a panel of selected drugs, including angiotensin-converting enzyme inhibitors (ACEIs: captopril, enalaprilate, lisinopril), angiotensin receptor blockers (ARBs: losartan and valsartan), furosemide and statins (pravastatin and simvastatin), and evaluated the drug-interactions using an OAT1-mediated fluorescein assay. We show that selected ARBs and furosemide significantly reduced fluorescein uptake, with the highest potency for ARBs. This was exaggerated in presence of some PBUTs. Selected ACEIs and statins had either no or a slight effect at supratherapeutic concentrations on OAT1-mediated fluorescein uptake. In conclusion, we demonstrate that PBUTs may compete with co-administrated drugs commonly used in CKD management for renal OAT1 mediated secretion, thus potentially compromising the residual renal function.

ACS Style

Silvia M. Mihaila; João Faria; Maurice F. J. Stefens; Dimitrios Stamatialis; Marianne C. Verhaar; Karin G. F. Gerritsen; Rosalinde Masereeuw. Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion. Toxins 2020, 12, 391 .

AMA Style

Silvia M. Mihaila, João Faria, Maurice F. J. Stefens, Dimitrios Stamatialis, Marianne C. Verhaar, Karin G. F. Gerritsen, Rosalinde Masereeuw. Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion. Toxins. 2020; 12 (6):391.

Chicago/Turabian Style

Silvia M. Mihaila; João Faria; Maurice F. J. Stefens; Dimitrios Stamatialis; Marianne C. Verhaar; Karin G. F. Gerritsen; Rosalinde Masereeuw. 2020. "Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion." Toxins 12, no. 6: 391.

Journal article
Published: 01 June 2020 in Tissue Engineering Part B: Reviews
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part B: Reviews 2020, 26, 198 -198.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part B: Reviews. 2020; 26 (3):198-198.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part B: Reviews 26, no. 3: 198-198.

Journal article
Published: 01 June 2020 in Tissue Engineering Part A
Reads 0
Downloads 0
ACS Style

Ying Chen; Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part A 2020, 26, 586 -586.

AMA Style

Ying Chen, Marianne Verhaar. Call for Special Issue Papers: Drugs and Disease Testing Model Systems. Tissue Engineering Part A. 2020; 26 (11-12):586-586.

Chicago/Turabian Style

Ying Chen; Marianne Verhaar. 2020. "Call for Special Issue Papers: Drugs and Disease Testing Model Systems." Tissue Engineering Part A 26, no. 11-12: 586-586.

Journal article
Published: 30 May 2020 in International Journal of Molecular Sciences
Reads 0
Downloads 0

In vascular tissue engineering strategies, the addition of vascular-specific extracellular matrix (ECM) components may better mimic the in vivo microenvironment and potentially enhance cell–matrix interactions and subsequent tissue growth. For this purpose, the exact composition of the human vascular ECM first needs to be fully characterized. Most research has focused on characterizing ECM components in mature vascular tissue; however, the developing fetal ECM matches the active environment required in vascular tissue engineering more closely. Consequently, we characterized the ECM protein composition of active (fetal) and quiescent (mature) renal arteries using a proteome analysis of decellularized tissue. The obtained human fetal renal artery ECM proteome dataset contains higher levels of 15 ECM proteins versus the mature renal artery ECM proteome, whereas 16 ECM proteins showed higher levels in the mature tissue compared to fetal. Elastic ECM proteins EMILIN1 and FBN1 are significantly enriched in fetal renal arteries and are mainly produced by cells of mesenchymal origin. We functionally tested the role of EMILIN1 and FBN1 by anchoring the ECM secreted by vascular smooth muscle cells (SMCs) to glass coverslips. This ECM layer was depleted from either EMILIN1 or FBN1 by using siRNA targeting of the SMCs. Cultured endothelial cells (ECs) on this modified ECM layer showed alterations on the transcriptome level of multiple pathways, especially the Rho GTPase controlled pathways. However, no significant alterations in adhesion, migration or proliferation were observed when ECs were cultured on EMILIN1- or FNB1-deficient ECM. To conclude, the proteome analysis identified unique ECM proteins involved in the embryonic development of renal arteries. Alterations in transcriptome levels of ECs cultured on EMILIN1- or FBN1-deficient ECM showed that these candidate proteins could affect the endothelial (regenerative) response.

ACS Style

Christian G.M. Van Dijk; Laura Louzao Martinez; Elise Van Mulligen; Bart Boermans; Jeroen A.A. Demmers; Thierry P.P. Van Den Bosch; Marie-José Goumans; Dirk J. Duncker; Marianne C. Verhaar; Caroline Cheng. Extracellular Matrix Analysis of Human Renal Arteries in Both Quiescent and Active Vascular State. International Journal of Molecular Sciences 2020, 21, 3905 .

AMA Style

Christian G.M. Van Dijk, Laura Louzao Martinez, Elise Van Mulligen, Bart Boermans, Jeroen A.A. Demmers, Thierry P.P. Van Den Bosch, Marie-José Goumans, Dirk J. Duncker, Marianne C. Verhaar, Caroline Cheng. Extracellular Matrix Analysis of Human Renal Arteries in Both Quiescent and Active Vascular State. International Journal of Molecular Sciences. 2020; 21 (11):3905.

Chicago/Turabian Style

Christian G.M. Van Dijk; Laura Louzao Martinez; Elise Van Mulligen; Bart Boermans; Jeroen A.A. Demmers; Thierry P.P. Van Den Bosch; Marie-José Goumans; Dirk J. Duncker; Marianne C. Verhaar; Caroline Cheng. 2020. "Extracellular Matrix Analysis of Human Renal Arteries in Both Quiescent and Active Vascular State." International Journal of Molecular Sciences 21, no. 11: 3905.